SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-135073
Filing Date
2023-05-04
Accepted
2023-05-04 07:46:01
Documents
13
Period of Report
2023-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d207223d8k.htm   iXBRL 8-K 24916
2 EX-99.1 d207223dex991.htm EX-99.1 135226
  Complete submission text file 0001193125-23-135073.txt   299753

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bbio-20230504.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20230504_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20230504_pre.xml EX-101.PRE 11264
7 EXTRACTED XBRL INSTANCE DOCUMENT d207223d8k_htm.xml XML 3348
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 23886566
SIC: 2834 Pharmaceutical Preparations